Petera29
4日前
Great Post.
If your company wants to keep out of trouble moving forward, do your Due Diligence on Jim Zimbler, Jim Morrison, and their attorney. Lying Eric Newlan.
Zimbler and Morrison hooked up together in a Zimbler controlled company Cannagistics, to buy Morrison’s holdings.
Zimbler left Cannagistics, Jim Morrison became CEO, and when Cannagistics ran out of money, Morrison did a “Fraudulent Transfer of Assets” owned by Cannagistics to Emergent Health which now was being run by Zimbler who illegally become the CEO of Emergent Health.with the help of their crooked lawyer Eric Newlan.
The Directors of MedWell should look up the Cannagistics assets that Jim Morrison illegally transfers to Emergent Health, then with the help of Eric Newlan helped as the lawyer for both Emergent Health and KOAN who helped orchestrated the illegal transfer of the Emergent assets to KOAN.
For the sake of your company and shareholders, distance yourself from Zimbler, Morrison, and Eric Newlan, all involved in SEC violations.
You should stop and illegal think, why doesn’t Jim Zimbler, Jim Morrison, of Eric Newlan sue me for writhing and accusing them for these illegal SEC and criminal transactions.
Well the answer is, EVERYTHING I have written is TRUE.
Why hasn’t the SEC, FBI, Attorney General or any other agencies come after these Scammers?
Hopefully it is only a matter of time.
Petera29
3週前
Based on the SEC Q3 report, must have Jim Zimbler (Felon, Liar, Thief) ) Jim Morrison (has been potential Felon) with their lawyer Eric Newlan as the lawyer for EMGE, KOAN committed a “Fraudulent Conveyance of Assets” from EMGE in a plan to avoid my “Default Judgement” for $450,000, cheating investors, BUT enhancing friends of Zimbler, and Morrison.
A little background on attorney,
Leonard Tucker a convicted Felon Permanently Barred from the Securities industry hired Eric Newlan to lawyer the Reg A Offering for Emergent Health.
On Aug.26,2021 we wired $250,000 to start the Reg A for Emergent Health.
On THAT same day Aug.26,2021 Frank Magliochetti and his UNDISCLOSED PARTNER Leonard Tucked by some means forced Dr John Cappello to sell then his Control Block of (66.7%) for $10.
SEC Rule Change of Control must be SEC reported in in a Form 8-K within 4 days after Change of Control.
In a FINRA report on Nov. 15,2021 Frank Magliochetti with assistance of Eric Newlan announced the Change of Control block that Frank Magliochetti and, NOT named (undisclosed partner Leonard Tucker) became the OWNERS of EMGE for $10.00
In June of 2022 Emergent Health borrowed $260,000 from a Jim Zimbler client Clayton Stuve and bought the CB back from Magliochetti and Tucker for $250,000 a deal negotiated Wimmer Jim Zimbler who illegally took the CB.
I have the signed “Stock Option Agreement” that either Eric Newlan or Frank and Leonard’s attorney (an other crook) Corain drafted which states, this Agreement entered by and between Leonard Tucker and Parcae Capital (Frank Magliochetti) the OWNERS that hold 66.67 shares will sell the CB for $250,000 for a total consideration of the $250,000 payable $125,000 to Leonard Tucker and $125,000 to Parcae.,
The Stock Option Agreement is signed and finalized by James Zimbler CEO of EMGE, Frank Magliochetti, and Leonard Tucker and their lawyer Corain McGinn.
ONLY IN AMERICA CAN 3 CONVICTED FELONS, ZIMBLER-MAGLIOCHETTI & TUCKER can own and SELL a PUBLIC companies Control Block, and as of today NEVER reported the circumstances that Eric Newlan knew to the SEC.
Enough for now.
Hopefully the SEC, FBI, Florida Attorney General, and the Texas Bar Association. Once they receive the enclosed information TAKE ACTION.
AveragePenny
1月前
$MWAI MedWell Ai, Inc Reports Q3 Revenues Of $618,676 And Provides Corporate Update
https://www.globenewswire.com/news-release/2026/05/06/3288871/0/en/MedWell-Ai-Inc-Reports-Q3-Revenues-Of-618-676-And-Provides-Corporate-Update.html
CLEARWATER, Fla., May 06, 2026 (GLOBE NEWSWIRE) -- via IBN -- MedWell Ai, Inc, (OTCQB:MWAI) ("Company") is a portfolio company, specializing in AI-driven solutions for B2B markets in pharmaceuticals, healthcare, and wellness sectors, is pleased to confirm the filing, of its Quarterly Report (Form 10-Q), for the financial period, ending on March 31, 2026.
Key Financial Highlights:
Increased Total Revenues:
For three months, ended March 31, 2026, Company had generated total revenues of $618,676 ($638,336 including deferred revenues) vs $281,318, for three months, ended March 31, 2025.
For nine months, ended March 31, 2026, Company had generated total revenues of $1,694,482 vs $425,327, for nine months, ended March 31, 2025.
The Company reconfirms yearly revenue guidance of $2.3 million.
Reduced Total Loss From Operations:
For three months, ended March 31, 2026, Company's net loss was reduced to $227,939 from $814,192, for three months, ended March 31, 2025.
For nine months, ended March 31, 2026, Company's net loss was reduced to $827,961 from $1,718,272, for nine months, ended March 31, 2025.
Reduced General And Administrative Expenses:
For three months, ended March 31, 2026, Company's expenses were reduced to $364,539 from $1,129,360, for three months, ended March 31, 2025.
For nine months, ended March 31, 2026, Company's expenses were reduced to $1,216,444 from $2,089,773, for nine months, ended March 31, 2025.
Reduced Net Loss Per Common Share:
For three months, ended March 31, 2026, Company's net loss was reduced to 0.039 cents vs 0.139 cents, for three months, ended March 31, 2025.
For nine months, ended March 31, 2026, Company's net loss was reduced to 0.178 cents vs 0.306 cents, for nine months, ended March 31, 2025.
Total Liabilities/Mezzanine/Stockholder's Deficit: As of March 31, 2026, Company's liabilities deficit was $321,787 vs $805,500, as of June 30, 2025.
Steve Rubakh, CEO of MedWell Ai, Inc, provides the following Corporate Update:
"During restructuring Phase (1), MWAI has focused on launching and expanding its AI-driven pharma/healthcare/wellness operations. Q3 financial results confirm top-line progress, driven by its B2B pharma procurement arm, MedWell USA, which markets high-demand in-office use, wellness products, like compounded GLP-1 agonists for weight management.
We believe that the Company is well positioned to move forward with execution of the next Phase (2), which includes strategic acquisition of multiple revenue generating and cash flow positive B2B assets to form Vertically Integrated Wellness Roll Up, consisting of (1) manufacturer and distributor of biologics, focused on exosome based regenerative products, (2) additional procurement agencies, similar to the MedWell USA, (3) technology software solutions company, to facilitate marketing, product procurement and automated transaction flow between healthcare providers and pharma suppliers and (4) infrastructure platform that provides specialized back-office management services for 503A pharmacies and pharmaceutical 503B manufacturers.
We believe that our current business strategy will enable MedWell Ai to capitalize on structural inefficiencies, benefit from increasing digitization and drive margin expansion in healthcare procurement, thus representing a unique, differentiated and scalable investment opportunity."
AveragePenny
3月前
$MWAI MedWell Ai Reports Strong Q2 Revenues Of $548,315 And Provides Guidance For Full Year 2025 Exceeding $2,200,000.
https://www.otcmarkets.com/stock/MWAI/news/MedWell-Ai-Reports-Strong-Q2-Revenues-Of-548315-And-Provides-Guidance-For-Full-Year-2025-Exceeding-2200000?id=511344
Clearwater, FL, February 23, 2026 / PRNewswire/ - MedWell Ai, Inc, (OTCQB: MWAI) (“Company”) is a portfolio company, specializing in AI-driven solutions for B2B markets in pharmaceuticals, healthcare, and wellness, is pleased to confirm the filing, after the market close, of its Quarterly Report (Form 10-Q), for the financial period, ending on December 31, 2025.
The Company reported $548,315 in Revenue for its fiscal second quarter of 2025. This performance was result of a successful strategic shift toward building an AI-driven healthcare, pharmaceutical and biological wellness portfolio.
Key Financial Highlights:
Increased Total Revenues:
· For three months, ended December 31, 2025, Company had generated total revenues of 548,315 vs $142,861 for three months, ended December 31, 2024 (280%+ increase).
· For six months, ended December 31, 2025, Company had generated total revenues of $1,075,806 vs $144,009 for six months, ended December, 2024 (700%+ increase).
Reduced Total Loss From Operations:
For three months, ended December 31, 2025, Company’s net loss was reduced to $266,221 vs $315,096 for three months, ended December 31, 2024.
For six months, ended December 31, 2025, Company’s net loss was reduced to $592,255 vs $904,080 for six months, ended December 31, 2024.
Reduced General And Administrative Expenses:
For three months, ended December 31, 2025, Company’s expenses were reduced to $388,509 vs $625,199 for three months, ended December 31, 2024.
For six months, ended December 31, 2025, Company’s expenses were reduced to $796,839 vs $960,413 for six months, ended December 31, 2024.
Reduced Net Loss Per Common Share:
For three months, ended December 31, 2025, Company’s net loss was reduced to 0.045 cents vs 0.062 cents for three months, ended December 31, 2024.
For six months, ended December 31, 2025, Company’s net loss was reduced to 0.138 cents vs 0.174 cents for six months, ended December 31, 2024.
Total Liabilities/Mezzanine/Stockholder’s Deficit: For three months, ended December 31, 2025, Company’s liabilities deficit was reduced to $468,655 from $805,500, for three months, ended June 30, 2025.
ihubstockmover
4月前
$MWAI - New MedWell Ai, Inc will be organized across three core divisions: (1) national pharma distribution and telemed platform, (2) nationwide portfolio of premium surgical and cosmetic centers and men’s healthcare franchise brand and (3) advanced biologics and product innovation group.
The Company will acquire, consolidate and operate the following divisions:
- Ageless Cosmetic Surgery Centers, Inc., headquartered in Garden City, NY.
- Apollo BioWellness, Inc. (OTC: KOAN) and its subsidiary Evolutionary Biologics, Inc and other aesthetic and cosmetic technologies and products.
- MedWell USA, LLC, currently operating and rapidly growing subsidiary, focused on:
(1) Distribution of GLP-1 and Peptides based products, manufactured by 503B facilities
(2) Soon to be launching TeleMD, LLC - 24/7 telehealth platform.
Based on trailing revenues of $14 million in 2025, the consolidated Company is projected to generate annual revenues, exceeding $25 million in 2026 (assuming adequate funding and successful closing), and conservative EBITDA margins of at least 20%.
All parties have begun the due diligence process with the goal of closing the transactions within 60 days.
Market Size: The Global Regenerative Medicine Market, a core component of the regenerative wellness ecosystem, was valued at approximately USD 35.5 billion in 2024 and is projected to reach over USD 169 billion by 2034, growing at a CAGR of roughly 16% to 23%. The broader global wellness economy, which includes elements of regenerative health, reached a record USD 6.3 trillion in 2023 and is forecasted to reach USD 9.8 trillion by 2029.
Projections: Market is anticipated to reach between USD 90 billion and USD 555 billion by 2032-2034, driven by advancements in stem cell therapies, gene editing, and tissue engineering. The industry is experiencing a robust CAGR, with estimates generally falling between 16% and 31%.
Market Drivers: North America is the leading market, accounting for over 58% of the global market share in 2024, supported by high healthcare spending and advanced biotech infrastructure. The U.S. market is projected to surpass USD 80 billion by 2033. Stem Cell and Gene Therapy: These subsegments are witnessing the fastest growth due to increased investment and regulatory approvals for treating genetic and degenerative disorders.
https://www.globenewswire.com/news-release/2026/02/10/3235507/0/en/MedWell-Ai-Executes-Letter-Of-Intent-To-Create-America-s-First-Vertically-Integrated-Regenerative-Wellness-Eco-System.html
AveragePenny
4月前
$MWAI MedWell Ai Executes Letter Of Intent To Create America's First Vertically Integrated Regenerative Wellness Eco-System
https://www.globenewswire.com/news-release/2026/02/10/3235507/0/en/MedWell-Ai-Executes-Letter-Of-Intent-To-Create-America-s-First-Vertically-Integrated-Regenerative-Wellness-Eco-System.html
CLEARWATER, Fla., Feb. 10, 2026 (GLOBE NEWSWIRE) -- via IBN – MedWell Ai, Inc ("Company") (OTCQB: MWAI) is pleased to announce the signing of a Letter of Intent (“LOI”) to create a vertically integrated health, wellness and longevity platform.
New MedWell Ai, Inc will be organized across three core divisions: (1) national pharma distribution and telemed platform, (2) nationwide portfolio of premium surgical and cosmetic centers and men’s healthcare franchise brand and (3) advanced biologics and product innovation group.
The Company will acquire, consolidate and operate the following divisions:
- Ageless Cosmetic Surgery Centers, Inc., headquartered in Garden City, NY.
- Apollo BioWellness, Inc. (OTC: KOAN) and its subsidiary Evolutionary Biologics, Inc and other aesthetic and cosmetic technologies and products.
- MedWell USA, LLC, currently operating and rapidly growing subsidiary, focused on:
(1) Distribution of GLP-1 and Peptides based products, manufactured by 503B facilities
(2) Soon to be launching TeleMD, LLC - 24/7 telehealth platform.
Based on trailing revenues of $14 million in 2025, the consolidated Company is projected to generate annual revenues, exceeding $25 million in 2026 (assuming adequate funding and successful closing), and conservative EBITDA margins of at least 20%.
All parties have begun the due diligence process with the goal of closing the transactions within 60 days.
Market Size: The Global Regenerative Medicine Market, a core component of the regenerative wellness ecosystem, was valued at approximately USD 35.5 billion in 2024 and is projected to reach over USD 169 billion by 2034, growing at a CAGR of roughly 16% to 23%. The broader global wellness economy, which includes elements of regenerative health, reached a record USD 6.3 trillion in 2023 and is forecasted to reach USD 9.8 trillion by 2029.
Projections: Market is anticipated to reach between USD 90 billion and USD 555 billion by 2032-2034, driven by advancements in stem cell therapies, gene editing, and tissue engineering. The industry is experiencing a robust CAGR, with estimates generally falling between 16% and 31%.
Market Drivers: North America is the leading market, accounting for over 58% of the global market share in 2024, supported by high healthcare spending and advanced biotech infrastructure. The U.S. market is projected to surpass USD 80 billion by 2033. Stem Cell and Gene Therapy: These subsegments are witnessing the fastest growth due to increased investment and regulatory approvals for treating genetic and degenerative disorders.
Steve Rubakh, CEO of MedWell Ai, comments:
“I am pleased to announce this consolidation to create a world-class state-of-the-art regenerative wellness company. By owning and aligning distribution, laboratories, biologics, and retail care models, MedWell Ai will create a complete wellness eco-system, designed to reduce supply chain inefficiencies, strengthen quality control, improve reliability, and enable disciplined national expansion through a scalable operating strategy. With the proposed consolidation, the Company intends to announce shortly, bringing a seasoned and talented management team to operate all three verticals. In addition, the Company is entertaining other additional strategic acquisitions it will be targeting in the coming months, as part of our quest to make MedWell Ai the #1 Regenerative Wellness & Medical Platform in the World".
dipbuy
7月前
MedWellAI (MWAI) – Q3 2025 Summary
Quick snapshot
- Quarter ended: Sept 30, 2025
- Revenue: $96.1k (vs $1.1k a year ago) – almost entirely new commission revenue.
- Operating loss: $(326k) (vs $(589k) last year).
- Net loss (to MedWellAI): $(652k) (vs $(1.22M) last year).
- Cash: $223k (down from $401k at June 30, 2025).
- Working capital: Current assets $242k vs current liabilities $7.53M (huge deficit).
- Stockholders’ equity: $(7.06M) deficit (worse than $(6.46M) at June 30).
The good ✅
Real revenue traction (vs. almost nothing last year)
- Commissions of $94.9k vs $0 a year ago, from the new B2B health/wellness / GLP meds channel.
- Online sales are tiny but stable ($1.2k vs $1.1k).
Losses are narrowing
- Operating loss improved to $(326k) from $(589k).
- Net loss nearly halved to $(652k) from $(1.24M), helped by the absence of big crypto-related losses and smaller discontinued-ops charges.
Digital asset / mining mess is basically behind them
- No new crypto trading or mining activity this quarter; no gain/loss from digital assets in continuing ops.
- Discontinued operations loss fell to $(72.7k) (mostly impairment) from $(584k) a year ago.
Cleanup of old preferred dividend overhang
- On Aug 1, 2025 they exchanged Series C & D preferred into a new Series C convertible preferred, and retired $2.13M of accrued unpaid dividends.
- Accounting-wise this did create a loss on exchange (~$242k), but structurally it removes a big accrued-dividend overhang.
Cash burn is moderate in absolute dollars
- Operating cash outflow was about $171k for the quarter (not millions).
The bad 🚫
Extremely weak balance sheet / going concern
- Current liabilities exceed current assets by ~$7.3M; total equity is a $(7.06M) deficit.
- The 10-Q explicitly states there is “substantial doubt” about the company’s ability to continue as a going concern.
Tiny revenue vs. cost base
- Quarterly revenue of $96k vs $422k of operating expenses – still very far from breakeven.
- General & administrative alone is $395k, including $162.5k in CEO compensation and $49k in stock-based comp.
Cash is low and falling, with no new financing this quarter
- Cash dropped from $401k to $223k in three months, and they did not raise new equity or debt this quarter.
Heavy, risky capital structure
- $500k note payable is in default, still outstanding.
- New Series C convertible preferred is booked as a current liability of $6.5M (variable share conversion, at holder’s option), sitting ahead of common in the stack.
- Related-party payable (accrued salary/bonus to the CEO) increased to $328k.
Shareholder dilution risk remains high
- 6.24M common shares outstanding now, plus:
- - 130k Series B preferred convertible into 100 common shares each (i.e., 13M common if fully converted),
- - 6,500 Series C convertible preferred with variable conversion pricing,
- - Additional unissued but granted stock for services.
Business is highly concentrated and early-stage
- Revenue is almost entirely from one new commissions-based health/wellness line; online DTC business has been exited due to regulatory hurdles.
- Company has basically one full-time executive (the CEO) and relies heavily on him, including for related-party advances.
Bottom line
Early-stage pivot from crypto/mining into AI-enabled GLP / wellness distribution, with real but still small revenue. Less loss than last year, but very weak balance sheet, low cash, going concern warning, defaulted debt, and big preferred stack ahead of the common.
AveragePenny
10月前
$MWAI MedWellAi, Inc Joins Trump Mobile In Engaging BrighterMD To Develop Ai-Inhanced Healthcare Telemedicine Platform, Focused On $24.46 Billion Corporate Wellness Market
https://www.prnewswire.com/news-releases/medwellai-inc-joins-trump-mobile-in-engaging-brightermd-to-develop-ai-inhanced-healthcare-telemedicine-platform-focused-on-24-46-billion-corporate-wellness-market-302531075.html
CLEARWATER, Fla., Aug. 18, 2025 /PRNewswire/ -- MedWell Ai, Inc, ("Company") (OTCQB: MWAI) is pleased to confirm the collaboration and execution of Software Development Agreement with BrighterMD, to develop and launch Company's latest initiative: TeleMD.Ai – Nationwide B2B and B2C Healthcare and Wellness Telemedicine Platform, with main focus on corporate healthcare benefits market.
Scheduled to go live in October, 2025, TeleMD is designed to deliver a comprehensive telehealth primary care that is affordable and accessible for everyone. Clients will be able to access all the healthcare care they need through TeleMd's platform and technology, easy-to-use desktop and mobile apps, resulting in getting timely healthcare advice, eliminating travel and wait time to schedule appointments.
This platform will offer (1) affordable monthly subscription plans (retail + corporate clients) with unlimited access to the healthcare providers and certified telehealth therapists, (2) nationwide 365/24/7 access via smart device or desktop, (3) no co-pays, no cancelation or any other additional fees/charges.
With innovative stack that includes Cloudflare, Google Font API, and Bootstrap, TeleMD is committed to leveraging technology for delivering healthcare services. BrighterMD solutions and their technology approach, provide an opportunity for TeleMD to offer their tech-savvy corporate clients with effective options on how to integrate the latest healthcare solutions into their current systems.
TeleMD Ai is focused on two markets segments: Business-To-Public And Business-To-Business.
> B2C – Affordable Pricing for Individuals & Families: TeleMd's solution is simple to use and allows anyone to access all the healthcare they need with an affordable monthly subscription. Users will have access to unlimited appointments, 24 hours a day from the comfort of their home or office.
> B2B – Discounted Group Pricing for Companies: TeleMD delivers affordable healthcare for your employees, while reducing premiums with high quality comprehensive telemedicine solution. Now, employers can offer extra benefits with primary care online, provide employees and their families with unlimited private appointments that won't be shared with insurers or employers. All employees can quickly and conveniently access team of medical professionals, as frequently as they need.
TeleMD is a simple and effective addition to any benefits package. Enrolling employees into the program is available via API integration, or via EDI file transfer. Simple to set up, easy to use. Company's goal is to provide a seamless, robust and affordable healthcare solution for employers to offer their employees. By choosing TeleMD's telehealth services, employers will reduce insurance premiums, while offering convenient and extensive primary care and mental health support to your employees that they can use whenever they need it. Note that all appointments are 100% confidential and no information is shared with employers or insurers. This service is a great option for part-time employees that aren't covered by insurance.
Key Platform Components:
* Primary Care Telemedicine: Access a team of board-certified doctors who can help clients with a variety of medical conditions. User can choose a phone or video call with doctors who will then diagnose symptoms and, if necessary, provide a prescription. Then, TeleMD will send, if required, prescription to client's choice pharmacy for hassle-free pickup. The Company intends to deploy custom AI Agents to provide real time personalised healthcare assessments, coaching and support. By analysing data from wearable devices, smart weight scales and patient-reported outcomes, Ai Agent will provide tailored recommendations and interventions that are optimised for each individual's unique needs and preferences.
* Telehealth Therapy Consultations: TeleMD facilitates quick and easy access for a teletherapy consult to discuss any mental health issues. Our therapists and counselors are on hand to provide support and talk, whenever patient needs them, anywhere in the US.
* MedWell Ai Exclusive - Life Style/Wellness Management/Discounted Pharma Products:
Weight Loss Management
Energy+Longevity
Men's Health
Women's Health
Dermatology
IV Therapy
Hormone Replacement
Sexual Health
SkinCare
* Behavioral & Mental Benefit Coverage: 365/24/7 access to licensed mental and behavioral health counselors and therapists - available by phone or video call with $0 copay. Additional services include: (1) Financial and Legal Consultations, (2) Life Coaching, (3) Medical Advocacy and (4) Nutritional Counseling. TeleMd's AI-enhanced platform will offer new ways to provide mental support and care. It will feature Ai Agent that can identify signs of depression or distress and provide on-the-go support, and connect individuals with human therapists when needed.
* Discounted Pharmacy RX Benefits: TeleMD's platform is uniquely connected to over 70,000 pharmacies and for members with immediate need, like antibiotic, etc, this plan provides access to the top 125 most prescribed medications at NO COST. Once patient completes video consult, the doctors will prescribe medication. The most common urgent/acute care drugs are available for immediate pick-up from preferred pharmacy. 90% of chronic condition meds home delivered at a $0 copay. 125 acute meds at any pharmacy at a $0 copay. TeleMD offers diabetes program at no added cost and OTC meds at a discount. Members save up to 80% on prescriptions; at most major RX retailers as well as 80% on any lab work at any Quest Diagnostics location.
* Bilingual Services: TeleMD differentiates itself by offering bilingual (English+Spanish) Board-Certified doctors and mental health therapists. This FREE feature could be a valuable selling point for many corporations with diverse workforces that seek healthcare solutions that cater to employees with varying language needs, presenting a market niche to target.
* Biometric Care/LifeVitals Scanner: TeleMD offers a FREE LifeVitals app, which provides accurate vital sign readings with the selfie camera on any iOS or Android phone. No bluetooth or hardware needed. Currently FDA Registered with clinical trials completed. 95% accuracy on key vital signs. Additional features/benefits: (1) get contactless blood pressure and heart rate monitoring, (2) only need smart device's camera—no extra equipment needed, (3) user can view real-time vitals and scan history, (4) share results with healthcare provider instantly and (5) track trends over time for better wellness insights.
* TelePetCare Solutions: This OPTIONAL low cost service provides access to licensed vets to handle client's pet's emergencies, regular check ups, prescriptions and more. Additional discounted services: (1) RX Prescriptions, (2) Lab Work, (3) Hearing Aids, (4) Eyecare and Vision exams, (5) Dental Coverage, (6) Gym/Wellness Memberships, (7) Everyday Life and COVID Testing (No-cost and unlimited).
Steve Rubakh, CEO of MedWell AI, Inc adds the following commentary: "MedWell Ai is pleased to join other established software providers and resellers like Trump Mobile, in retaining BrighterMD to develop TeleMD.Ai – 100% corporately owned telemedicine solution. This platform l allows clients to take complete control of everyday health and wellness. It's the easy, reliable, and effective option to stay well. Setting up a telemedicine consult through TeleMD is a very simple process. It offers: (1) no need for travel, no wait times — healthcare help is available from anywhere, (2) fast access to the licensed and trusted providers for initial consult, RXs or for follow -up care, (3) all-in-one solution, consisting of medical/mental healthcare, prescriptions and biometric tracking and (4) 365/24/7 access that provides peace of mind. As the cost of traditional health insurance and related co-pays continue to rise, TeleMd's goal to ensure that all clients and employees are getting timely and comprehensive access to the healthcare they need. Our low cost monthly membership structure makes primary care, rx's and mental health services affordable for everyone."